-

ForgeRock, Inc. (FORG) Investor Alert: Contact Robbins LLP if You Have Concerns Regarding the Acquisition of ForgeRock, Inc. by Thoma Bravo

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors it is investigating the acquisition of ForgeRock, Inc. (NYSE: FORG) by Thoma Bravo. Under the terms of the agreement, ForgeRock stockholders will receive $23.25 in cash for each share of ForgeRock common stock owned.

If you own shares of ForgeRock, Inc., click here.

Is the Proposed Acquisition Best for ForgeRock, Inc. (FORG) and Its Shareholders?

In October 2022, ForgeRock announced a deal to be acquired by private-equity firm Thoma Bravo. According to the Proxy Statement, ForgeRock's board approved a merger agreement with Thoma Bravo for $23.25 per share in cash. The deal is valued at approximately $2.31 billion and is expected to close the first half of 2023. Robbins LLP is concerned that ForgeRock's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Next Steps: If you own shares of ForgeRock, Inc. (FORG) you have legal options. Contact us to learn more about your legal rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against ForgeRock, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:FORG

Release Summary
Is the Proposed Acquisition of ForgeRock, Inc. (FORG) by Thoma Bravo Best for ForgeRock, Inc. (FORG) and Its Shareholders?
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Place, Suite 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom